Video

The larger the "A," the more likely you are to pay the cost of negative dysphotopsia

Author(s):

Kassi Filkins
Conferences|ASCRS

Mark Packer, MD, discusses the causes, factors, and treatments of negative dysphotopsia.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
Related Content
Apellis announces 5 abstracts to be orally presented at the American Society of Retina Specialists (ASRS) annual meeting
July 15th 2025

Apellis announces 5 abstracts to be orally presented at the American Society of Retina Specialists (ASRS) annual meeting

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Study data link cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair
July 10th 2025

Study data link cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

(Image credit: AdobeStock/sakurra) Balwantray C. Chauhan, PhD: In vivo functional imaging of single retinal ganglion cells with two-photon imaging
July 7th 2025

Balwantray C. Chauhan, PhD, explores in vivo functional imaging of single retinal ganglion cells with two-photon imaging

Lupin receives FDA approval for Loteprednol Etabonate Ophthalmic Gel, 0.38%
July 3rd 2025

Lupin receives FDA approval for Loteprednol Etabonate Ophthalmic Gel, 0.38%

© 2025 MJH Life Sciences

All rights reserved.